GSA Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $766K | Sell |
40,921
-3,765
| -8% | -$70.5K | 0.05% | 632 |
|
|
2025
Q1 | $804K | Buy |
+44,686
| New | +$804K | 0.07% | 483 |
|
|
2024
Q3 | – | Sell |
-90,245
| Closed | -$742K | – | 1948 |
|
|
2024
Q2 | $742K | Sell |
90,245
-47,708
| -35% | -$392K | 0.05% | 716 |
|
|
2024
Q1 | $2.04M | Sell |
137,953
-4,751
| -3% | -$70.3K | 0.16% | 96 |
|
|
2023
Q4 | $2.07M | Buy |
142,704
+45,560
| +47% | +$661K | 0.17% | 107 |
|
|
2023
Q3 | $1.05M | Buy |
97,144
+61,281
| +171% | +$662K | 0.09% | 368 |
|
|
2023
Q2 | $463K | Buy |
35,863
+3,423
| +11% | +$44.2K | 0.05% | 791 |
|
|
2023
Q1 | $428K | Buy |
32,440
+22,913
| +241% | +$302K | 0.04% | 814 |
|
|
2022
Q4 | $143K | Buy |
+9,527
| New | +$143K | 0.02% | 1254 |
|
|
2021
Q4 | – | Sell |
-11,504
| Closed | -$418K | – | 1740 |
|
|
2021
Q3 | $418K | Buy |
+11,504
| New | +$418K | 0.04% | 806 |
|
|
2021
Q2 | – | Sell |
-1,604
| Closed | -$55K | – | 1557 |
|
|
2021
Q1 | $55K | Buy |
+1,604
| New | +$55K | 0.01% | 1027 |
|
|
2020
Q3 | – | Sell |
-8,443
| Closed | -$155K | – | 1366 |
|
|
2020
Q2 | $155K | Sell |
8,443
-14,112
| -63% | -$259K | 0.09% | 405 |
|
|
2020
Q1 | $352K | Sell |
22,555
-1,994
| -8% | -$31.1K | 0.09% | 380 |
|
|
2019
Q4 | $525K | Buy |
24,549
+4,436
| +22% | +$94.9K | 0.06% | 616 |
|
|
2019
Q3 | $376K | Buy |
+20,113
| New | +$376K | 0.05% | 735 |
|
|
2018
Q4 | – | Sell |
-2,790
| Closed | -$90K | – | 1679 |
|
|
2018
Q3 | $90K | Buy |
+2,790
| New | +$90K | 0.01% | 1567 |
|
|
2014
Q2 | – | Sell |
-1,328
| Closed | -$52K | – | 1937 |
|
|
2014
Q1 | $52K | Buy |
+1,328
| New | +$52K | ﹤0.01% | 1513 |
|